Compare HOVR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HOVR | RFL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 61.1M |
| IPO Year | N/A | 2017 |
| Metric | HOVR | RFL |
|---|---|---|
| Price | $1.81 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.33 | N/A |
| AVG Volume (30 Days) | ★ 454.6K | 92.9K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.35 | $1.12 |
| 52 Week High | $4.18 | $3.19 |
| Indicator | HOVR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 48.08 |
| Support Level | $1.70 | $1.15 |
| Resistance Level | $1.90 | $1.38 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 27.14 | 30.00 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.